RNS Number : 4547E
Synairgen plc
29 June 2023
 

 


Synairgen plc

('Synairgen' or the 'Company')

Results of Annual General Meeting

 


Southampton, UK - 29 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. All resolutions proposed at its Annual General Meeting were passed.

The full results of the proxy voting and text of the resolutions can be viewed by visiting the Company's website at www.Synairgen.com.

 

 

For further enquiries, please contact:

 

finnCap (NOMAD and Joint Broker) 

Geoff Nash, Charlie Beeson (Corporate Finance) 

Alice Lane, Sunil de Silva (ECM) 

Tel: + 44 (0) 20 7220 0500 

 

Numis Securities Limited (Joint Broker) 

Freddie Barnfield, Duncan Monteith, Euan Brown 

Tel: + 44 (0) 20 7260 1000 

 

Consilium Strategic Communications (Financial Media and Investor Relations) 

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone 

cscsynairgen@consilium-comms.com 

Tel: +44 (0) 20 3709 5700 

 

MKC STRATEGIES, LLC (US Media Relations) 

Mary Conway 

MConway@MKCStrategies.com    

Tel: +1 516-606-6545 

 

 

 

 

Notes for Editors 

 

About Synairgen  

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBRGDLBGDDGXC